Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.05.004Source: DataRank Database

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 2.0. It has been cited 66 times, with 62 citing works in its 1-hop citation network.

N/A

2.0DataRank · unranked

Scored on demand from live citation data

Open Access66 citations · 62 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 5.50)OA: greenTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 31%Citation Network 69%

Base Score Contribution

0.631

From this paper's citation signal

Citation Network Contribution

1.4

From 42 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 62 citers.

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
Haematologica202313 citations29 referencesContributes 0.091
Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy
Blood Advances202340 citations41 referencesContributes 0.091
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Journal for ImmunoTherapy of Cancer20224 citations18 referencesContributes 0.089
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation202313 citations31 referencesContributes 0.085
Fluctuation of physical function during chimeric antigen receptor T‐cell therapy during rehabilitation intervention: Real‐world data and risk factor analyses
eJHaem20247 citations25 referencesContributes 0.083

Authors (17)

Amylou C. Dueck ORCID,Gita Thanarajasingam ORCID,Joan M. Griffin ORCID,Carrie A. Thompson ORCID,Urshila Durani ORCID

Live enrichment

PubMed:35550440 PMC:PMC9357185 OpenAlex:https://openalex.org/W4229377559

Mayo Clinic

Grant: 2K12CA090628-21

American Society of Clinical Oncology

Grant: KL2TR003143

NCI NIH HHS

Grant: P30 CA015083

NCI NIH HHS

Grant: K12 CA090628

NCI NIH HHS

Grant: P50 CA186781

Pfizer

Mayo Clinic

Janssen Pharmaceuticals

Takeda Pharmaceutical Company

AbbVie

National Institutes of Health

Celgene

National Cancer Institute

Bristol-Myers Squibb

Spectrum Pharmaceuticals

FWCI

5.50

Citation Percentile

1.0%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9357185

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/9357185

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9357185

publisherhttps://api.elsevier.com/content/article/PII:S2666636722012726?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722012726?httpAccept=text/plain

Fields of Study

CAR-T cell therapy researchMedicine

MeSH Terms

Patient Reported Outcome MeasuresReceptors, Chimeric AntigenHumansProspective StudiesQuality of LifeTransplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell Transplantation

Keywords

MedicineCommon Terminology Criteria for Adverse EventsQuality of life (healthcare)Adverse effectTransplantationClinical endpointSurgeryInternal medicineProspective cohort studyClinical trialCognitionQuality of lifeAdverse EventsPatient-reported OutcomesPatient ExperienceChimeric Antigen ReceptorCar-t Therapy

Sustainable Development Goals

SDG 0: Quality Education